Lirilumab
Modify Date: 2025-09-08 08:15:09
Lirilumab structure
|
Common Name | Lirilumab | ||
|---|---|---|---|---|
| CAS Number | 1000676-41-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LirilumabLirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2]. |
| Name | Lirilumab |
|---|
| Description | Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2]. Animal Model: Rag1KO-Tg KIR mice injected with tumor cells[2] Dosage: 15 mg/kg Administration: intravenous injection; 15 mg/kg; once Result: Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died. |
| References |
| No Any Chemical & Physical Properties |